Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple c...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2023-09-01
|
| Serie: | Current Problems in Cancer: Case Reports |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2666621923000339 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|